Homocysteine and vascular disease in diabetes: a double hit?
Cardiovascular disease is a major problem in diabetes, and risk factors presumably unrelated to diabetes, such as hyperhomocysteinaemia, may be related to the development of cardiovascular complications in diabetic individuals. Plasma homocysteine levels are usually normal in diabetes, although both lower and higher levels have been reported. Homocysteine levels in diabetes are modulated by hyperfiltration and renal dysfunction, as well as low folate status. Insulin resistance does not appear to be a major determinant of plasma homocysteine level. Hyperhomocysteinaemia has been associated with microalbuminuria and retinopathy in type 1 and type 2 diabetes. In patients with type 2 diabetes, plasma homocysteine concentration is a significant predictor of cardiovascular events and death. This relation seems to be stronger in subjects with diabetes than without. The underlying pathophysiological mechanism of this increased vascular risk remains unexplained, but may be related to worsening of endothelial dysfunction and/or structural vessel properties induced by oxidative stress. Because homocysteine and diabetes have apparent synergistic detrimental vascular effects, patients with diabetes are candidates for screening and treatment with folic acid until the results of ongoing clinical trials are available.
Huijberts
Maya S P
MS
Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands.
Becker
Annemarie
A
Stehouwer
Coen D A
CD
D048909:Diabetes Complications / Q000097:blood* / Q000150:complications* / Q000473:pathology; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D014652:Vascular Diseases / Q000097:blood* / Q000150:complications* / Q000473:pathology
D006710:Homocysteine